一个多中心的随机生物等价性研究,对一个新型的即时使用的Temozolomide口服悬浮剂与Temozolomide囊进行了对比
François Ducray1, Carole Ramirez2, Marie Robert3
1Service de Neuro-Oncologie, Hôpital Neurologique, Hospices Civils de Lyon, Centre de Recherche en Cancérologie UMR INSERM 1052 CNRS 5286, Université Claude Bernard Lyon 1, 69008 Lyon, France.
Pharmaceutics
|December 23, 2023
概括
新的儿科Temozolomide (Ped-TMZ) 口服悬浮剂与标准口服囊具有生物相当性. 这项研究证实了它在治疗儿童神经母细胞瘤方面的安全性和有效性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
- 临床药房 临床药房
背景情况:
- 泰莫佐洛米德 (TMZ) 口服悬浮剂 (Ped-TMZ) 是一种用于治疗复发性或耐药性神经母细胞瘤的新型儿科配方.
- 该研究评估了与现有的口服TMZ囊相比,Ped-TMZ的安全性和生物等价性.
研究的目的:
- 评估一种新的儿科用Temozolomide (TMZ) 口服悬浮剂的安全性和生物等价性.
- 为了比较这种新的配方与标准的口服TMZ囊.
主要方法:
- 一个I期,多中心,随机,开放标签,交叉,单剂量生物等价性研究.
- 36名患有脑瘤的成年患者接受了Ped-TMZ悬浮剂和TMZ囊.
- 通过比较Cmax和AUCt比率在90%的置信区间内评估生物等价性.
主要成果:
- 两种Ped-TMZ和TMZ囊都显示出快速的体外溶解特征.
- 生物等价性得到证实,AUCt和Cmax比率在80-125%的范围内.
- 没有观察到Ped-TMZ的意外安全信号或局部毒性.
结论:
- 佩德-TMZ口服悬浮剂和TMZ口服囊是生物同等和立即释放的配方.
- 这项研究支持使用Ped-TMZ作为儿童神经母细胞瘤治疗的安全有效替代方案.
相关概念视频
Bioequivalence: Overview
1.0K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.0K
Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K


